This inventor holds 1 USPTO granted patent. Top assignee: Kinomica Limited. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Pedro Rodriquez Cutillas: Innovator in Acute Myeloid Leukaemia Treatment
Introduction
Pedro Rodriquez Cutillas is a notable inventor based in London, GB. He has made significant contributions to the field of medical research, particularly in the treatment of acute myeloid leukaemia (AML). His innovative work focuses on improving patient outcomes through targeted therapies.
Latest Patents
Rodriquez Cutillas holds a patent for his invention titled "Stratification of acute myeloid leukaemia patients for sensitivity to kinase pathway inhibitor therapy." This invention relates to the treatment of AML in patients. It concerns improved methods for identifying AML patients who may be effectively treated with kinase pathway inhibitors. Additionally, it provides methods for predicting the efficacy of these inhibitors for individual patients. The invention also includes a method for screening multiple patients suffering from AML to determine their suitability for kinase pathway inhibitor treatment.
Career Highlights
Throughout his career, Pedro Rodriquez Cutillas has been dedicated to advancing cancer treatment methodologies. His work has been instrumental in developing strategies that enhance the effectiveness of therapies for AML patients. He is associated with Kinomica Limited, where he continues to contribute to innovative research in the field.
Collaborations
Rodriquez Cutillas collaborates with various professionals in the medical research community. One of his notable coworkers is Pedro Maria Casado Izquierdo, with whom he has worked closely on projects related to cancer treatment.
Conclusion
Pedro Rodriquez Cutillas is a pioneering inventor whose work in the treatment of acute myeloid leukaemia has the potential to significantly improve patient care. His innovative approaches and dedication to research exemplify the impact of targeted therapies in modern medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile